Randomised placebo controlled trial of β agonist dose reduction in asthma

Harrison, T. W.; Oborne, J.; Wilding, P. J.; Tattersfield, A. E.
February 1999
Thorax;Feb1999, p98
Academic Journal
No abstract available.


Related Articles

  • Cardiovascular Safety of Î’ 2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease. Salpeter, Shelley R. // Drugs & Aging;2004, Vol. 21 Issue 6, p405 

    Background: β2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality. Methods: A systematic review of...

  • Montelukast. Markham, A.; Faulds, D. // Drugs;Aug1998, Vol. 56 Issue 2, p251 

    â–´ Montelukast is a selective antagonist of the leukotriene D (LTD) receptor. In patients with asthma, montelukast 5 to 250 mg/day attenuated LTD-induced bronchoconstriction and, at a dosage of 10mg, significantly reduced early and late airway response to allergen (dust mite extract)...

  • Do Inhaled β2-Agonists have an Ergogenic Potential in Non-Asthmatic Competitive Athletes? Kindermann, Wilfried // Sports Medicine;2007, Vol. 37 Issue 2, p95 

    The prevalence of asthma is higher in elite athletes than in the general population. The risk of developing asthmatic symptoms is the highest in endurance athletes and swimmers. Asthma seems particularly widespread in winter-sport athletes such as cross-country skiers. Asthmatic athletes...

  • Review: long acting β agonists increase severe asthma exacerbations and asthma related deaths in children and adults. Salpeter, S. R.; Buckley, N. S.; Ormiston, T. M. // Evidence Based Medicine;Feb2007, Vol. 12 Issue 1, p10 

    The article presents a study regarding the use of long acting beta agonists in patients with asthma. In assessing the study, a randomized controlled trials that compared salmeterol, formoterol or eformoterol with placebo are employed. The results suggest that long acting beta agonists increase...

  • Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre sandomised double-blind placebo-controlled trial. Brusselle, Guy G.; VanderStichele, Christine; Jordens, Paul; Deman, René; Slabbynck, Hans; Ringoet, Veerle; Verleden, Geert; Demedts, Ingel K.; Verhamme, Katia; Delporte, Anja; Demeyere, Bénédicte; Claeys, Geert; Boelens, Jerina; Padalko, Elizaveta; Verschakelen, Johny; Maele, Georges Van; Deschepper, Ellen; Joos, Guy F. P. // Thorax;Apr2013, Vol. 68 Issue 4, p322 

    Background Patients with severe asthma are at increased risk of exacerbations and lower respiratory tract infections (LRTI). Severe asthma is heterogeneous, encompassing eosinophilic and non-eosinophilic (mainly neutrophilic) phenotypes. Patients with neutropilic airway diseases may benefit from...

  • Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Douglas C Cowan // Thorax;Oct2010, Vol. 65 Issue 10, p891 

    BACKGROUND: Statins have anti-inflammatory actions which in theory are potentially beneficial in asthma. Small trials have failed to show a significant benefit, but a systematic study to evaluate the steroid-sparing effect of statin treatment has not been carried out. METHODS: A randomised,...

  • The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Brodlie, Malcolm; McKean, Michael C.; Moss, Samantha; Spencer, David A. // Archives of Disease in Childhood;Jul2012, Vol. 97 Issue 7, p604 

    Objective To report the oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Design 16-week therapeutic trial. Setting Tertiary paediatric asthma clinic. Patients 34 children with severe asthma maintained on oral prednisolone (median age 12 years; 15 children <12...

  • Meta-Analysis: Respiratory Tolerance to Regular β2-Agonist Use in Patients with Asthma. Salpeter, Shelley R.; Ormiston, Thomas M.; Salpeter, Edwin E. // Annals of Internal Medicine;5/18/2004, Vol. 140 Issue 10, p802 

    Background: The regular administration of β2-agonists may be associated with the development of tolerance to their effects. Purpose: To assess the effect of regular β2-agonist use on respiratory function and β2-receptor function in asthmatic patients. Data Sources: Comprehensive...

  • Montelukast: A Review of its Therapeutic Potential in Persistent Asthma. Jarvis, B.; Markham, A. // Drugs;Apr2000, Vol. 59 Issue 4, p891 

    Montelukast is a cysteinyl leukotriene receptor antagonist used to treat persistent asthma in patients aged ≥6 years. The drug has a rapid onset of action. Improvements in lung function and reductions in as-needed β-agonist usage are apparent within 1 day of initiating montelukast...

  • Review: allergen specific immunotherapies reduce symptoms, medication requirements, and bronchial hyper-reactivity in asthma. Abramson, M. J.; Puy, R. M.; Weiner, J. M. // Evidence Based Medicine;Jul/Aug2004, Vol. 9 Issue 4, p114 

    The article presents a study on allergen specific (AS) immunotherapy for asthma. 75 randomised controlled trials met the selection criteria. Patients who received AS immunotherapy had greater symptomatic improvement, had reduced asthma medication requirements, and were less likely to develop...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics